3M Drug Delivery Systems has designed a proof-of-concept device using a solid microstructured transdermal system (sMTS) for the systemic delivery of high potency pharmaceuticals. The technology was showcased this week at the annual meeting of the Controlled Release Society in New York, where John K. Simons, Ph.D., microstructured transdermal project manager at the company, explained the in vivo data, including depth of penetration, timed release, and demonstration of systemic delivery.

The research findings showed that the delivery of naloxone via an sMTS patch was comparable to a subcutaneous injection with regard to bioavailability and pharmacokinetic (PK) profile. Time-release data showed that the dosage was delivered quickly after the patch was placed on the skin, with the majority of the initial array content delivered within 30 seconds. This data along with the systemic delivery studies, confirmed that efficient systemic delivery is possible with coated microstructures. 3M's sMTS technology was previously used for vaccine delivery and this new application expands the range of APIs that can be delivered transdermally.
   
"This technology will help pharmaceutical providers differentiate their products with a minimally invasive and more comfortable self-administration method," said Dr. Simons.